iPS Cells for Modelling and Treatment of Retinal Diseases
Centre for Ophthalmology and Visual Science (Incorporating Lions Eye Institute), The University of Western Australia, Perth WA 6009, Australia
Ophthalmology Department, Royal Perth Hospital, Perth WA 6009, Australia
Control of Pluripotency Laboratory, Department of Physiological Sciences I, Faculty of Medicine, University of Barcelona, Hospital Clinic, Casanova 143, Barcelona 08036, Spain
School of Medicine and Pharmacology, University of Western Australia, Crawley, Perth WA 6009, Australia
Faculty of Medicine, Westmead Children's Hospital, Division of Paediatrics and Child Health, University of Sydney Medical School, Sydney NSW 2145, Australia
Developmental and Stem Cell Biology, Victor Chang Cardiac Research Institute, Sydney NSW 2145, Australia
Department of Vitreoretinal Surgery, Moorfields Eye Hospital, London EC1V 2PD, UK
Division of Cellular Therapy, Institute of Ophthalmology, University College of London, London EC1V 9EL, UK
Author to whom correspondence should be addressed.
Received: 22 September 2014 / Revised: 16 November 2014 / Accepted: 18 November 2014 / Published: 19 December 2014
For many decades, we have relied on immortalised retinal cell lines, histology of enucleated human eyes, animal models, clinical observation, genetic studies and human clinical trials to learn more about the pathogenesis of retinal diseases and explore treatment options. The recent availability of patient-specific induced pluripotent stem cells (iPSC) for deriving retinal lineages has added a powerful alternative tool for discovering new disease-causing mutations, studying genotype-phenotype relationships, performing therapeutics-toxicity screening and developing personalised cell therapy. This review article provides a clinical perspective on the current and potential benefits of iPSC for managing the most common blinding diseases of the eye: inherited retinal diseases and age-related macular degeneration.
This is an open access article distributed under the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
Share & Cite This Article
MDPI and ACS Style
Chen, F.K.; McLenachan, S.; Edel, M.; Da Cruz, L.; Coffey, P.J.; Mackey, D.A. iPS Cells for Modelling and Treatment of Retinal Diseases. J. Clin. Med. 2014, 3, 1511-1541.
Chen FK, McLenachan S, Edel M, Da Cruz L, Coffey PJ, Mackey DA. iPS Cells for Modelling and Treatment of Retinal Diseases. Journal of Clinical Medicine. 2014; 3(4):1511-1541.
Chen, Fred K.; McLenachan, Samuel; Edel, Michael; Da Cruz, Lyndon; Coffey, Peter J.; Mackey, David A. 2014. "iPS Cells for Modelling and Treatment of Retinal Diseases." J. Clin. Med. 3, no. 4: 1511-1541.
Show more citation formats
Show less citations formats
[Return to top]
For more information on the journal statistics, click here
Multiple requests from the same IP address are counted as one view.